Zai Lab ( NASDAQ: ZLAB ) reported positive topline data from a Phase 3 study in China for KarXT in the treatment of schizophrenia. The Chinese company said the study , a registrational bridging trial, met its primary endpoint and all key secondary endpoints. Based on.
